Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 57, 5093-5099, November 15, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, B. M.
Right arrow Articles by Gerson, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, B. M.
Right arrow Articles by Gerson, S. L.

Selection for G156A O6-Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Protection from Lethality in Mice Treated with O6-Benzylguanine and 1,3-Bis(2-chloroethyl)-1-nitrosourea1

Brian M. Davis, Jane S. Reese, Omer N. Koç, Keunmyoung Lee, Jane E. Schupp and Stanton L. Gerson2

Division of Hematology/Oncology and Molecular Virology Training Program, Case Western Reserve University, University Hospitals of Cleveland Ireland Cancer Center, Cleveland, Ohio 44106

A retroviral gene therapy approach was developed to protect early hematopoietic progenitors from 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a stem cell toxin, and O6-benzylguanine (BG), an inhibitor of a key BCNU resistance protein, O6-alkylguanine DNA alkyltransferase (AGT). The retroviral vector MFG was used to transfer the G156A MGMT ({Delta}MGMT) cDNA, encoding a mutant AGT that is resistant to inhibition by BG, into murine bone marrow-derived hematopoietic progenitors. Following transplantation into lethally irradiated mice, the transduced cells were subjected to in vivo BG and BCNU treatment to examine the ability to enrich for transduced cells expressing {Delta}AGT. Transplantation of {Delta}MGMT-transduced cells resulted in {delta}AGT expression in 30% of bone marrow nucleated cells 13 weeks after transplantation. After one cycle of BG and BCNU, {Delta}AGT expression was observed in 60% of bone marrow cells, and the percentage of colony-forming units (culture; CFU-C) containing proviral sequence increased from 67 to 100%. CFU-C obtained from BG and BCNU-treated {Delta}MGMT animals up to 23 weeks after transplantation were more resistant to combination BG and BCNU than CFU-C from mice transplanted with lacZ-transduced cells and treated with BG and BCNU or from mice transplanted with {Delta}MGMT-transduced cells and left untreated. The degree of drug resistance in {Delta}MGMT-transduced hematopoietic progenitors to BG and BCNU was much greater than we observed previously with wild-type MGMT gene transfer and treatment with BCNU alone. Furthermore, whereas 21 of 22 mice transplanted with {Delta}MGMT-transduced cells survived in vivo BG and BCNU administration, only 3 of 13 mice transplanted with lacZ-transduced progenitors survived similar drug treatment. Thus, {Delta}MGMT-transduced murine bone marrow cells selectively survive in vivo BG and BCNU exposure, resulting in prolonged enrichment for the transduced cells and protection from mortality induced by this drug combination.

1 This work was supported in part by USPHS Grants P30CA43703, RO1CA63193, RO1ES06288, RO1CA73062, and UO1CA75525.

2 To whom requests for reprints should be addressed, at Division of Hematology/Oncology, Case Western Reserve University Hospital, BRB-3W, 10900 Euclid Avenue, Cleveland, OH 44106-4937. Phone: (216) 368-1176; Fax: (216) 368-1166.

Received 4/18/97. Accepted 9/19/97.




This article has been cited by other articles:


Home page
BloodHome page
B. C. Beard, R. Sud, K. A. Keyser, C. Ironside, T. Neff, S. Gerull, G. D. Trobridge, and H.-P. Kiem
Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients
Blood, May 21, 2009; 113(21): 5094 - 5103.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. D. Milsom, M. Jerabek-Willemsen, C. E. Harris, A. Schambach, E. Broun, J. Bailey, M. Jansen, D. Schleimer, K. Nattamai, J. Wilhelm, et al.
Reciprocal Relationship between O6-Methylguanine-DNA Methyltransferase P140K Expression Level and Chemoprotection of Hematopoietic Stem Cells
Cancer Res., August 1, 2008; 68(15): 6171 - 6180.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. M. Fontes, B. M. Davis, L. P. Encell, K. Lingas, D. T. Covas, M. A. Zago, L. A. Loeb, A. E. Pegg, and S. L. Gerson
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells
Mol. Cancer Ther., January 1, 2006; 5(1): 121 - 128.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-R. Lee, S.-H. Kim, H.-J. Cho, K.-Y. Lee, A. R. Moon, H. G. Jeong, J.-S. Lee, J.-W. Hyun, M.-H. Chung, and H. J. You
Transcription Factors NF-YA Regulate the Induction of Human OGG1 Following DNA-alkylating Agent Methylmethane Sulfonate (MMS) Treatment
J. Biol. Chem., March 12, 2004; 279(11): 9857 - 9866.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. L. Kreklau, K. E. Pollok, B. J. Bailey, N. Liu, J. R. Hartwell, D. A. Williams, and L. C. Erickson
Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea
Mol. Cancer Ther., December 1, 2003; 2(12): 1321 - 1329.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. L. Sweeney, J. L. Frandsen, C. M. Verfaillie, and R. S. McIvor
Trimetrexate Inhibits Progression of the Murine 32Dp210 Model of Chronic Myeloid Leukemia in Animals Expressing Drug-resistant Dihydrofolate Reductase
Cancer Res., March 15, 2003; 63(6): 1304 - 1310.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. L. Gerson
Clinical Relevance of MGMT in the Treatment of Cancer
J. Clin. Oncol., May 1, 2002; 20(9): 2388 - 2399.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. A. Warlick, M. D. Diers, J. E. Wagner, and R. S. McIvor
In Vivo Selection of Antifolate-Resistant Transgenic Hematopoietic Stem Cells in a Murine Bone Marrow Transplant Model
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 50 - 56.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Kobune, Y. Xu, C. Baum, M. R. Kelley, and D. A. Williams
Retrovirus-mediated Expression of the Base Excision Repair Proteins, Formamidopyrimidine DNA Glycosylase or Human Oxoguanine DNA Glycosylase, Protects Hematopoietic Cells from N,N',N''-Triethylenethiophosphoramide (thioTEPA)-induced Toxicity in Vitro and in Vivo
Cancer Res., July 1, 2001; 61(13): 5116 - 5125.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. R. Belur, D. Boelk-Galvan, M. D. Diers, R. S. McIvor, and C. L. Zimmerman
Methotrexate Accumulates to Similar Levels in Animals Transplanted with Normal versus Drug-resistant Transgenic Marrow
Cancer Res., February 1, 2001; 61(4): 1522 - 1526.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
S. Ragg, M. Xu-Welliver, J. Bailey, M. D’Souza, R. Cooper, S. Chandra, R. Seshadri, A. E. Pegg, and D. A. Williams
Direct Reversal of DNA Damage by Mutant Methyltransferase Protein Protects Mice against Dose-intensified Chemotherapy and Leads to in Vivo Selection of Hematopoietic Stem Cells
Cancer Res., September 1, 2000; 60(18): 5187 - 5195.
[Abstract] [Full Text]


Home page
BloodHome page
B. M. Davis, O. N. Koc, and S. L. Gerson
Limiting numbers of G156A O6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection
Blood, May 15, 2000; 95(10): 3078 - 3084.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. A. Persons and A. W. Nienhuis
Gene therapy for the hemoglobin disorders: Past, present, and future
PNAS, May 9, 2000; 97(10): 5022 - 5024.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Maze, C. Kurpad, A. E. Pegg, L. C. Erickson, and D. A. Williams
Retroviral-Mediated Expression of the P140A, but not P140A/G156A, Mutant Form of O6-Methylguanine DNA Methyltransferase Protects Hematopoietic Cells against O6-Benzylguanine Sensitization to Chloroethylnitrosourea Treatment
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1467 - 1474.
[Abstract] [Full Text]


Home page
MutagenesisHome page
B. J. Glassner, G. Weeda, J. M. Allan, J. L.M. Broekhof, N. H.E. Carls, I. Donker, B. P. Engelward, R. J. Hampson, R. Hersmus, M. J. Hickman, et al.
DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents
Mutagenesis, May 1, 1999; 14(3): 339 - 347.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
G. D. LeSage, S. S. Glaser, L. Marucci, A. Benedetti, J. L. Phinizy, R. Rodgers, A. Caligiuri, E. Papa, Z. Tretjak, A.-M. Jezequel, et al.
Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver
Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1289 - G1301.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Xu-Welliver, J. Leitao, S. Kanugula, and A. E. Pegg
Alteration of the Conserved Residue Tyrosine-158 to Histidine Renders Human O6-Alkylguanine-DNA Alkyltransferase Insensitive to the Inhibitor O6-Benzylguanine
Cancer Res., April 1, 1999; 59(7): 1514 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Reese, B. M. Davis, L. Liu, and S. L. Gerson
Simultaneous Protection of G156A Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Sensitization of Tumor Cells Using O6-Benzylguanine and Temozolomide
Clin. Cancer Res., January 1, 1999; 5(1): 163 - 169.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. M. Davis, L. P. Encell, S. P. Zielske, F. C. Christians, L. Liu, S. E. Friebert, L. A. Loeb, and S. L. Gerson
Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells
PNAS, April 24, 2001; 98(9): 4950 - 4954.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.